Royal Bank Of Canada Issues Positive Forecast for Maricann Group (CNSX:MARI) Stock Price

Maricann Group (CNSX:MARI) had its price objective hoisted by equities research analysts at Royal Bank Of Canada from $6.00 to $16.00 in a research note issued to investors on Wednesday,BayStreet.CA reports.

Other equities analysts also recently issued research reports about the company. Beacon Securities raised their price target on Maricann Group from $12.00 to $15.00 and gave the stock a “buy” rating in a research report on Tuesday, August 26th. Raymond James Financial boosted their target price on shares of Maricann Group from $6.50 to $11.50 in a research note on Thursday, August 21st. Finally, BMO Capital Markets raised their price target on shares of Maricann Group from $12.00 to $13.00 in a research note on Wednesday, August 27th. Three equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $13.30.

Maricann Group Stock Performance

Maricann Group has a twelve month low of $0.87 and a twelve month high of $3.60.

Maricann Group Company Profile

Maricann Group Inc, formerly Danbel Industries Corporation, is a Canada-based integrated producer and distributor of marijuana for medical purposes. As one of approximately 43 companies with a federal license to cultivate cannabis and one of approximately 30 independent licensed producers with a federal license to process and distribute cannabis, the Company’s services a patient base with more than 8,000 registered patients.